SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 24, 2009-- Exelixis, Inc. (NASDAQ:EXEL) announced today that it will hold its Fifth Annual R&D Day on Wednesday, December 2, 2009 from 10:00 a.m. EST / 7:00 a.m. PST to 2:00 p.m. EST / 11:00 a.m. PST in New York. Exelixis management will discuss the company’s development pipeline, corporate strategy and financial outlook.

The event will be available via conference call and webcast. To listen to the call, please dial 866.730.5767 (domestic) or 857.350.1591 (international) and enter the passcode 69576914. The webcast may be accessed on the Event Calendar page under Investors at http://www.exelixis.com. An archive of this webcast will be available until 12:00 a.m. EST on January 2, 2010 or 9:00 p.m. PST on January 1, 2010.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis’ broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, sanofi-aventis, GlaxoSmithKline, Genentech, Boehringer Ingelheim, Wyeth Pharmaceuticals (acquired by Pfizer Inc.), and Daiichi-Sankyo. For more information, please visit the company’s web site at http://www.exelixis.com.

Exelixis and the Exelixis logo are registered U.S. trademarks.

Source: Exelixis, Inc.

Exelixis, Inc.
Investor Contact:
Charles Butler, 650-837-7277
Vice President, Investor Relations
and Corporate Communications
cbutler@exelixis.com
or
DeDe Sheel, 650-837-8231
Associate Director, Investor Relations
dsheel@exelixis.com